Cuban HB vaccine undergoes clinical trials in 8 countries

Cuban HB vaccine undergoes clinical trials in 8 countries

Monday, October 26, 2015

Print this page Email A Friend!

HAVANA, Cuba (Xinhua) -- A new Cuban vaccine for hepatitis B is undergoing clinical trials in seven Asian countries apart from Cuba, the Contemporanea newspaper reported Thursday.

The seven countries are Australia, New Zealand, South Korea, Singapore, China, The Philippines and Thailand, said Iris Lugo, a specialist from the Center for Genetic Engineering and Biotechnology (CIGB), which developed the vaccine.

The vaccine, HeberNasvac, prevents the progression of the disease or keeps it under control for a longer time, causes fewer adverse reactions, according to the CIGB. The treatment period is shorter, not exceeding 20 weeks.

Moreover, clinical trials have shown that the vaccine has greater antiviral efficacy than other applied conventional drugs.

Within a few months, Lugo said, the drug is expected to obtain the sanitary registration granted by the Center for State Control of Drugs and Medical Devices, allowing it to be used in Cuba in 2016.

The scientist added that some foreign companies have shown interest in its marketing, including French company Abivax, which has been involved with the development of the new vaccine.

According to the World Health Organisation, about one million people die each year from diseases related to the hepatitis B virus, which also continues to be the main risk factor for liver cancer and other serious complications, including esophageal varices.

Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at




1. We welcome reader comments on the top stories of the day. Some comments may be republished on the website or in the newspaper � email addresses will not be published.

2. Please understand that comments are moderated and it is not always possible to publish all that have been submitted. We will, however, try to publish comments that are representative of all received.

3. We ask that comments are civil and free of libellous or hateful material. Also please stick to the topic under discussion.

4. Please do not write in block capitals since this makes your comment hard to read.

5. Please don't use the comments to advertise. However, our advertising department can be more than accommodating if emailed:

6. If readers wish to report offensive comments, suggest a correction or share a story then please email:

7. Lastly, read our Terms and Conditions and Privacy Policy

comments powered by Disqus



Today's Cartoon

Click image to view full size editorial cartoon